A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients

Matias A. Bustos, Rebecca Gross, Negin Rahimzadeh, Hunter Cole, Linh T. Tran, Kevin D. Tran, Ling Takeshima, Stacey L. Stern, Steven O’Day, Dave S. B. Hoon

Open source

DOI
10.3390/cancers12113361
Published
2020-11-13
Container
Cancers
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers12113361,
  title = {A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients},
  author = {Matias A. Bustos and Rebecca Gross and Negin Rahimzadeh and Hunter Cole and Linh T. Tran and Kevin D. Tran and Ling Takeshima and Stacey L. Stern and Steven O’Day and Dave S. B. Hoon},
  year = {2020},
  journal = {Cancers},
  doi = {10.3390/cancers12113361},
  url = {https://doi.org/10.3390/cancers12113361}
}

RIS

TY  - JOUR
TI  - A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients
AU  - Matias A. Bustos
AU  - Rebecca Gross
AU  - Negin Rahimzadeh
AU  - Hunter Cole
AU  - Linh T. Tran
AU  - Kevin D. Tran
AU  - Ling Takeshima
AU  - Stacey L. Stern
AU  - Steven O’Day
AU  - Dave S. B. Hoon
PY  - 2020
JO  - Cancers
DO  - 10.3390/cancers12113361
UR  - https://doi.org/10.3390/cancers12113361
ER  - 

APA

Bustos, M. A., Gross, R., Rahimzadeh, N., Cole, H., Tran, L. T., Tran, K. D., Takeshima, L., Stern, S. L., O’Day, S., & Hoon, D. S. B. (2020). A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients. Cancers. https://doi.org/10.3390/cancers12113361

Source records